StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)

Close on Nov 17, 2026Market cap $264.95MP/E –Yield –

Prelude Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Prelude Therapeutics

Prelude Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Prelude Therapeutics figures

See a number that looks wrong?